[{"abstract": "Pfizer proposed a $99 billion acquisition of its British rival AstraZeneca that would allow it to reincorporate in Britain.", "web_url": "https://dealbook.nytimes.com/2014/04/28/pfizer-proposes-a-marriage-and-a-move-to-britain-easing-taxes/", "snippet": "Pfizer proposed a $99 billion acquisition of its British rival AstraZeneca that would allow it to reincorporate in Britain.", "lead_paragraph": "Pfizer, the maker of best-selling drugs like Lipitor and Viagra and a symbol of business prowess in the United States for more than a century, no longer wants to be an American company.", "print_section": "A", "print_page": "1", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/29/business/subDrug/subDrug-articleLarge.jpg", "height": 400, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/04/29/business/subDrug/subDrug-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 400}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/29/business/subDrug/subDrug-jumbo.jpg", "height": 682, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/29/business/subDrug/subDrug-superJumbo.jpg", "height": 1332, "width": 2000, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/29/business/subDrug/subDrug-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/04/29/business/subDrug/subDrug-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/29/business/subDrug/subDrug-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer Proposes a Marriage With AstraZeneca, Easing Taxes in a Move to Britain", "kicker": "DealBook", "content_kicker": null, "print_headline": "Pfizer Proposes a Marriage and a Move to Britain, Easing Taxes", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2014-04-29T01:16:59+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By David Gelles and Michael J. de la Merced", "person": [{"firstname": "David", "middlename": null, "lastname": "Gelles", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}, {"firstname": "Michael", "middlename": "J.", "lastname": "de la Merced", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 2}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/a01cb7f9-9fa5-5388-a92e-9bcc9c0807de", "word_count": 1304, "uri": "nyt://article/a01cb7f9-9fa5-5388-a92e-9bcc9c0807de"}, {"abstract": "Energy Future Holdings files for bankruptcy. | Pfizer makes a bid to move abroad with deal for AstraZeneca. | Bank of America\u2019s $4 billion accounting error. | France continues efforts to shield its economy.", "web_url": "https://dealbook.nytimes.com/2014/04/29/morning-agenda-a-failure-in-texas/", "snippet": "Energy Future Holdings files for bankruptcy. | Pfizer makes a bid to move abroad with deal for AstraZeneca. | Bank of America\u2019s $4 billion accounting error. | France continues efforts to shield its economy.", "lead_paragraph": "The troubled Texas utility Energy Future Holdings \u2012 which, as TXU, was private equity\u2019s biggest-ever buyout \u2012 filed for bankruptcy on Tuesday, Julie Creswell and Michael J. de la Merced write in DealBook. After months of on-again, off-again talks between the company, its owners and creditors, Energy Future Holdings went into Chapter 11 protection with a plan meant to avoid months in bankruptcy court in what will be one of the biggest Chapter 11 filings in history.", "source": "The New York Times", "multimedia": [], "headline": {"main": "A Failure in Texas", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2014-04-29T12:41:55+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Sydney Ember", "person": [{"firstname": "Sydney", "middlename": null, "lastname": "Ember", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/c1be7834-cbba-556a-b8cf-09ddd30547fa", "word_count": 1984, "uri": "nyt://article/c1be7834-cbba-556a-b8cf-09ddd30547fa"}, {"abstract": "The biggest charm of Pfizer\u2019s offer for AstraZeneca lies in switching to a lower-tax domicile, a strategy that is sure to be duplicated, Robert Cyran writes for Reuters Breakingviews.", "web_url": "https://dealbook.nytimes.com/2014/04/29/pfizer-most-likely-just-the-tip-of-the-tax-sword/", "snippet": "The biggest charm of Pfizer\u2019s offer for AstraZeneca lies in switching to a lower-tax domicile, a strategy that is sure to be duplicated, Robert Cyran writes for Reuters Breakingviews.", "lead_paragraph": "Pfizer\u2019s $99 billion tax arbitrage bid will encourage copycats. The biggest charm of the United States drug giant\u2019s offer for AstraZeneca of Britain lies in switching to a lower-tax domicile. The latest and largest such deal to hit the headlines raises the odds Congress will tighten rules \u2013 but not yet.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/29/business/dealbook/dbpix-pfizer-tax/dbpix-pfizer-tax-articleLarge.jpg", "height": 400, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/04/29/business/dealbook/dbpix-pfizer-tax/dbpix-pfizer-tax-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 400}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/29/business/dealbook/dbpix-pfizer-tax/dbpix-pfizer-tax-jumbo.jpg", "height": 683, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/29/business/dealbook/dbpix-pfizer-tax/dbpix-pfizer-tax-superJumbo.jpg", "height": 1365, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/29/business/dealbook/dbpix-pfizer-tax/dbpix-pfizer-tax-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/04/29/business/dealbook/dbpix-pfizer-tax/dbpix-pfizer-tax-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/29/business/dealbook/dbpix-pfizer-tax/dbpix-pfizer-tax-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer Most Likely Just the Tip of the Tax Sword", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Corporate Taxes", "rank": 1, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 2, "major": "N"}, {"name": "subject", "value": "Relocation of Business", "rank": 3, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 5, "major": "N"}], "pub_date": "2014-04-29T16:55:38+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Robert Cyran", "person": [{"firstname": "Robert", "middlename": null, "lastname": "Cyran", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/82897b38-93c5-59ba-b409-2587a5ff6158", "word_count": 416, "uri": "nyt://article/82897b38-93c5-59ba-b409-2587a5ff6158"}, {"abstract": "We don\u2019t know if Pfizer is targeting a British rival because the combined firm will be more efficient or because of the tax savings, Victor Fleischer writes in his Standard Deduction column.", "web_url": "https://dealbook.nytimes.com/2014/04/29/how-tax-laws-distort-the-pfizer-deal/", "snippet": "We don\u2019t know if Pfizer is targeting a British rival because the combined firm will be more efficient or because of the tax savings, Victor Fleischer writes in his Standard Deduction column.", "lead_paragraph": "The United States tax code is fueling Pfizer Inc.\u2019s $98.7 billion bid to take over the London-based pharmaceutical company AstraZeneca. If the deal goes through as proposed, a new parent company in Britain would own the combined entity, making it easier for the new firm to strip income out of its American tax base. The deal is one of several recent transactions known as \u201cinversions,\u201d where a multinational company like Pfizer, based in New York, becomes an expatriate by acquiring a smaller foreign target.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/30/business/dbpix-viagra/dbpix-viagra-articleLarge.jpg", "height": 407, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/04/30/business/dbpix-viagra/dbpix-viagra-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 407}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/30/business/dbpix-viagra/dbpix-viagra-jumbo.jpg", "height": 695, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/30/business/dbpix-viagra/dbpix-viagra-superJumbo.jpg", "height": 1254, "width": 1848, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/30/business/dbpix-viagra/dbpix-viagra-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/04/30/business/dbpix-viagra/dbpix-viagra-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/30/business/dbpix-viagra/dbpix-viagra-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "How Tax Laws Distort the Pfizer Deal", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2014-04-29T19:56:01+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Victor Fleischer", "person": [{"firstname": "Victor", "middlename": null, "lastname": "Fleischer", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/521599db-1fca-597c-8642-46e84452abe8", "word_count": 971, "uri": "nyt://article/521599db-1fca-597c-8642-46e84452abe8"}]